Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Authors
Hanna, C. R.O'Cathail, S. M.
Graham, J. S.
Saunders, Mark P
Samuel, L.
Harrison, M.
Devlin, L.
Edwards, J.
Gaya, D. R.
Kelly, C. A.
Lewsley, L. A.
Maka, N.
Morrison, P.
Dinnett, L.
Dillon, S.
Gourlay, J.
Platt, J. J.
Thomson, F.
Adams, R. A.
Roxburgh, C. S. D.
Affiliation
Cancer Research UK Glasgow Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Level 0, 1053 Great Western Road, Glasgow, G12 0YN, UK.Issue Date
2021
Metadata
Show full item recordCitation
Hanna CR, O’Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, et al. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) Vol. 16, Radiation Oncology. Springer Science and Business Media LLC; 2021.Journal
Radiotherapy and OncologyDOI
10.1186/s13014-021-01941-zPubMed ID
34857017Type
Otherae974a485f413a2113503eed53cd6c53
10.1186/s13014-021-01941-z
Scopus Count
Collections
Related articles
- Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
- Authors: Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD
- Issue date: 2021 Aug 26
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
- Authors: Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC
- Issue date: 2021 Jun
- The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
- Authors: Ursprung S, Mossop H, Gallagher FA, Sala E, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD
- Issue date: 2021 Nov 18
- The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.
- Authors: Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A
- Issue date: 2018 Feb
- A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
- Authors: Moe A, Liow E, Redfern A, Swarbrick N, Ferguson T, Davis ID, Hayne D
- Issue date: 2021 Oct